All News GT Biopharma, Inc.

Equities

GTBP

US36254L3087

Market Closed - Nasdaq Other stock markets 01:30:00 28/06/2024 am IST			5-day change	1st Jan Change
2.82 ^USD	-7.08%		-1.05%	-63.14%

27/06	GT Biopharma Says FDA Clears Investigational New Drug Application for Cancer Drug GTB-3650	MT
27/06	GT Biopharma Shares Rise on FDA Clearance for Cancer-Drug Study	DJ

All News

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

GT Biopharma Says FDA Clears Investigational New Drug Application for Cancer Drug GTB-3650	27/06	MT
GT Biopharma Shares Rise on FDA Clearance for Cancer-Drug Study	27/06	DJ
GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-3650, an NK Cell Engager for Treatment of CD33+ Leukemia	27/06	AQ
GT Biopharma, Inc. Announces FDA Clearance of Investigational New Drug Application for GTB-3650, an NK Cell Engager for Treatment of CD33+ Leukemia	27/06	CI
GT Biopharma, Inc. Announces CFO Changes	08/06	CI
Top Midday Decliners	21/05	MT
GT Biopharma Prices $3.2 Million Registered Direct Offering of Shares, Concurrent Private Placement of Warrants	21/05	MT
GT Biopharma, Inc. Announces $3.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules	21/05	AQ
Top Premarket Gainers	20/05	MT
GT Biopharma Reports First Quarter 2024 Financial Results and Provides Corporate Update	16/05	AQ
GT Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	16/05	CI
GT Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27/03	CI
GT Biopharma Reports Fourth Quarter and Full-Year 2023 Financial Results	27/03	AQ
GT Biopharma to Conduct 1-for-30 Reverse Stock Split; Shares Fall	01/02	MT
GT Biopharma, Inc. Announces 1-for-30 Reverse Stock Split	01/02	AQ
LEADING PROXY ADVISORY FIRMS, ISS AND GLASS LEWIS, RECOMMEND GT BIOPHARMA STOCKHOLDERS VOTE 'FOR' ALL PROPOSED ITEMS AT THE UPCOMING SPECIAL MEETING OF STOCKHOLDERS	07/12	AQ
Leading Proxy Advisory Firms, ISS and Glass Lewis, Recommend GT Biopharma Stockholders Vote “FOR” All Proposed Items at the Upcoming Special Meeting of Stockholders	06/12	AQ
GT Biopharma Announces IND Submission for GTB-3650 for Treatment of CD33+ Leukemia	04/12	AQ
GT Biopharma Announces IND Submission for GTB-3650 for Treatment of CD33+ Leukemia	04/12	CI
GT BIOPHARMA PRESENTED POSITIVE PRECLINICAL DATA FOR GTB-5550, A NOVEL TRIKE MOLECULE FOR TARGETED PROSTATE CANCER TREATMENT DURING THE SOCIETY FOR IMMUNOTHERAPY OF CANCER 2023 ANNUAL MEETING	07/11	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News GT Biopharma, Inc.

Equities

GTBP

US36254L3087

All News

Filters